Mass drug treatment for lymphatic filariasis and onchocerciasis

Trends in Parasitology

Volumn 19, Issue 11, 2003, Pages 516-522

  Molyneux, David H ^a   Bradley, Mark ^b   Hoerauf, Achim ^c   Kyelem, Dominique ^d   Taylor, Mark J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^d Ministry of Health   (Burkina Faso)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIBIOTIC AGENT; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; MILBEMYCIN; MOXIDECTIN; RIFAMPICIN;

DISEASE TRANSMISSION; DRUG DISTRIBUTION; DRUG MONITORING; FILARIASIS; HUMAN; LOA LOA; MEDICAL ASSESSMENT; MEDICAL RESEARCH; MICROFILARIA; NONHUMAN; ONCHOCERCIASIS; REDUCTION; REVIEW; WORM;

LOA LOA; NEMATODA;

EID: 0142258167     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.09.004     Document Type: Review

References (54)

1. Molyneux D.H. Onchocerciasis control in West Africa: current status and future of onchocerciasis control programmes. Parasitol. Today. 11:1995;399-402.
2. Richards F.O. Jr, et al. Control of onchocerciasis today: status and challenges. Trends Parasitol. 17:2001;558-563.
3. Benton B., et al. Partnership and promise: evolution of the African river-blindness campaigns. Ann. Trop. Med. Parasitol. 96:2002;S5-S14.
4. Ottesen E.A., et al. Strategies and tools for the control/elimination of lymphatic filariasis. Bull. WHO. 75:1997;491-503.
5. Molyneux D.H., Zagaria N. Lymphatic filariasis elimination: progress in global programme development. Ann. Trop. Med. Parasitol. 96:2002;S15-S40.
6. Molyneux D.H., Taylor M.J. Current status and future prospects of the Global Lymphatic Filariasis Programme. Curr. Opin. Infect. Dis. 14:2001;155-159.
7. Richards F., et al. Programmatic goals and approaches to onchocerciasis. Lancet. 355:2000;1663-1664.
8. Abiose A., et al. Onchocerciasis control strategies. Lancet. 356:2000;1523-1524.
9. Gardon J., et al. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 360:2002;203-209.
10. Drameh P.S., et al. Ten years of NGDO action against river blindness. Trends Parasitol. 18:2002;378-380.
11. Boorsboom G.J.J.M., et al. Impact of ivermectin on onchocerciasis transmission. Assessing the empirical evidence that repeated mass treatments may lead to elimination/eradication in West Africa. Filaria J. 2:2003;8.
12. Gyapong J.O., et al. The use of spatial analysis in mapping the distribution of bancroftian filariasis in four West African countries. Ann. Trop. Med. Parasitol. 96:2002;695-705.
13. ® auf Mikrofilarien von Onchocerca volvulus and Mansonella perstans in Patienten. Mitteilungen-Österreichischen Gesellschaft für Tropenmedizin und Parastiologie. 12:1990;179-184.
14. Van den Enden E., et al. Treatment failure of a single high dose of ivermectin for Mansonella perstans filariasis. Trans. R. Soc. Trop. Med. Hyg. 87:1993;90.
15. Gardon J., et al. Efficacy of repeated doses of ivermectin against Mansonella perstans. Trans. R. Soc. Trop. Med. Hyg. 96:2002;325-326.
16. Dadzie Y., et al. Final report of the conference on the eradicability of onchocerciasis. Filaria J. 2:2003;2.
17. Winnen M., et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull. WHO. 80:2002;384-391.
18. Tagboto S., Townson S. Antiparasitic properties of medicinal plants and other naturally occurring products. Adv. Parasitol. 50:2001;199-295.
19. Trees A.J., et al. Onchocerca ochengi infections in cattle as model for human onchocerciasis: recent developments. Parasitology. 120:2000;S133-S142.
20. Tchakouté C.L., et al. Chemoprophylaxis of Onchocerca infections: in a controlled, prospective study ivermectin prevents calves becoming infected with O. ochengi. Parasitology. 118:1999;195-199.
21. Taylor M.J., Hoerauf A. A new approach to the treatment of filariasis. Curr. Opin. Infect. Dis. 14:2001;717-718.
22. Townson S., et al. Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi. Ann. Trop. Med. Parasitol. 94:2000;801-816.
23. Hoerauf A., et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet. 355:2000;1242-1243.
24. Hoerauf A., et al. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet. 357:2001;1415-1416.
25. Hoerauf A., et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect. 5:2003;261-273.
26. Taylor M.J., et al. Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J. Exp. Med. 191:2000;1429-1436.
27. Cross H.F., et al. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet. 358:2001;1873-1875.
28. Keiser P.B., et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J. Infect. Dis. 185:2002;805-811.
29. Hoerauf, A. et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med. Microbiol. Immunol., (Berl.) (in press).
30. Sherchand J.B., et al. Mapping of lymphatic filariasis in Nepal. Filaria J. 2:2003;7.
31. Gardon J., et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 350:1997;18-22.
32. Boussinesq M., et al. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am. J. Trop. Med. Hyg. 58:1998;461-469.
33. Kamgno J., Boussinesq M. Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia. Parasite. 9:2002;59-63.
34. Tasgue-Dongmo L., et al. Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. Ann. Trop. Med. Parasitol. 96:2002;707-715.
35. Takougang I., et al. Rapid assessment method for prevalence and intensity of Loa loa infection. Bull. World Health Organ. 80:2002;852-858.
36. Thomson M.C., et al. Satellite mapping of Loa loa prevalence in relation to ivermectin use in western central Africa. Lancet. 356:2000;1077-1078.
37. McGarry H.F., et al. Evidence against Wolbachia symbiosis in Loa loa. Filaria J. 2:2003;9.
38. Büttner D.W., et al. Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa. Filaria J. 2:2003;10.
39. Dunyo S.K., Simonsen P.E. Ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana: follow-up after re-treatment with the combination. Trans. R. Soc. Trop. Med. Hyg. 96:2002;189-192.
40. Oostburg B.F.J. Is wuchereriasis a disappearing disease in Suriname? Acta Leiden. 53:1985;37-50.
41. Shaoqing Z., et al. A successful control programme for lymphatic filariasis in Hubei, China. Trans. R. Soc. Trop. Med. Hyg. 88:1994;510-512.
42. Bockarie M.J., et al. Mass treatment to eliminate filariasis in Papua New Guinea. N. Engl. J. Med. 347:2002;1841-1848.
43. Gelband H. Diethylcarbamazine salt in the control of lymphatic filariasis. Am. J. Trop. Med. Hyg. 50:1994;655-662.
44. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. 121:(Suppl 1):2000;S113-S132.
45. Pani S.P., et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital-based study. Filaria J. 1:2002;1.
46. Bradley M., Horton J. Assessing the risk of benzimidazole therapy during pregnancy. Trans. R. Soc. Trop. Med. Hyg. 95:2001;72-73.
47. Shenoy T.K., et al. The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. Ann. Trop. Med. Parasitol. 96:2002;603-614.
48. Awadzi K. O. volvulus resistance to ivermectin: evidence for resistance and resistance monitoring in the field. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J. 2:2003;2.
49. Ali M.M. Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis. Acta Trop. 84:2002;49-53.
50. Esterre P., et al. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop. Med. Int. Health. 6:2001;190-195.
51. Huang Y.J., Prichard R.K. Identification and stage-specific expression of two putative P-glycoprotein coding genes in Onchocerca volvulus. Mol. Biochem. Parasitol. 102:1999;273-281.
52. Prichard R., et al. O. volvulus resistance to ivermectin: is it occurring? lessons from the veterinary field, with thoughts on surveillance for resistance. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J. 2:2003;2.
53. Grant W. How real is the threat of ivermectin resistance in O. volvulus? Final report of the Conference on the eradicability of Onchocerciasis. Filaria J. 2:2003;2.
54. Shoop W. Ivermectin and moxidectin are cross-resistant in nematodes and the rate of development is the same. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J. 2:2003;2.